Martin John Shott
Vorsitzender bei European Pharmaceuticals Group Ltd.
Profil
Martin John Shott is currently the Chairman at European Pharmaceuticals Group Ltd.
and a Member at Royal Pharmaceutical Society of Great Britain.
He previously worked as the Director-Pharmaceutical Operations at Vectura Group Ltd., Associate Director-Research & Development at Innovata Biomed Ltd., Senior Manager at Novartis AG, and Senior Manager at Lers-Synthelabo.
Dr. Shott holds a doctorate degree from The University of Nottingham.
Aktive Positionen von Martin John Shott
| Unternehmen | Position | Beginn |
|---|---|---|
European Pharmaceuticals Group Ltd.
 European Pharmaceuticals Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Cardinal Health, Inc., European Pharmaceuticals Group Ltd. is a holding British company with investments in subsidiary undertakings engaged in pharmaceuticals. The company is based in Romford, UK. European Pharmaceuticals Group was acquired by The Intercare Group Plc from Groenwondt Beheer Bv on September 17, 1999 for $40.03 million. | Vorsitzender | 15.09.2010 |
Royal Pharmaceutical Society of Great Britain
 Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | 15.09.2010 |
Ehemalige bekannte Positionen von Martin John Shott
| Unternehmen | Position | Ende |
|---|---|---|
| Lers-Synthelabo | Corporate Officer/Principal | - |
Innovata Biomed Ltd.
 Innovata Biomed Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Philip Morris International, Inc., Innovata Biomed Ltd. engages in the research, development, and commercialization of respiratory drug delivery technologies. The company is based in Edinburgh, UK. | Technik-/Wissenschafts-/F&E-Leiter | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
| VECTURA GROUP | Geschäftsführer | 25.11.2011 |
Ausbildung von Martin John Shott
| The University of Nottingham | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NOVARTIS AG | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Vectura Group Ltd.
 Vectura Group Ltd. Pharmaceuticals: MajorHealth Technology Vectura Group Ltd. engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom. | Health Technology |
Royal Pharmaceutical Society of Great Britain
Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
Innovata Biomed Ltd.
Innovata Biomed Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Philip Morris International, Inc., Innovata Biomed Ltd. engages in the research, development, and commercialization of respiratory drug delivery technologies. The company is based in Edinburgh, UK. | Commercial Services |
European Pharmaceuticals Group Ltd.
European Pharmaceuticals Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Cardinal Health, Inc., European Pharmaceuticals Group Ltd. is a holding British company with investments in subsidiary undertakings engaged in pharmaceuticals. The company is based in Romford, UK. European Pharmaceuticals Group was acquired by The Intercare Group Plc from Groenwondt Beheer Bv on September 17, 1999 for $40.03 million. | Health Technology |
| Lers-Synthelabo |
